Osteoarthritis therapy
March 5, 2014
Glucosamine and chondroitin
sulphate have been examined in
combination for their effect on joint
space narrowing in the knees of
osteoarthritis sufferers in a study
from the University of Sydney.
The two year randomised, doubleblind,
placebo-controlled clinical
trial was conducted in people with
symptomatic knee osteoarthritis,
a condition that continues to be a
leading cause of ‘years lived with
disability’ around the globe.
“Many Australians purchase
glucosamine and/or chondroitin
supplements to relieve joint pain,
and in the hope that this will slow
the rate of joint destruction and
cartilage loss,” said ceo of the
Complementary Healthcare Council
of Australia, Carl Gibson.
The results of the study indicated
that daily doses of 1500mg of
glucosamine sulphate (Sanofi-
Aventis) and 800mg of chondroitin
sulphate (Pureflex, TSI) resulted in
a statistically significant decrease
of joint space narrowing, when
compared with placebo.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Mar 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Mar 14
